TMDX Stock Risk & Deep Value Analysis
Transmedics Group Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About TMDX Stock
We analyzed Transmedics Group Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TMDX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
TMDX Risk Analysis & Red Flags
What Could Go Wrong
While TMDX leads its niche, the organ transplant market is inherently limited in patient volume compared to broader medical device markets. If OCS adoption rates plateau or competitors (even those less technologically advanced) find ways to gain traction with simpler/cheaper alternatives, or if regulatory bodies slow future approvals, TMDX's growth could be constrained, impacting its ability to achieve truly exponential returns.
Risk Matrix
Overall
Moderate
Financial
Medium
Market
Low
Competitive
Low
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Decelerating revenue growth guidance (from 37% in FY25 to 20-25% in 2026) suggests a maturing initial growth curve.
- ⚠
The previous analysis noted a projected 250bps hit to operating margins for 2026, which needs close monitoring for actual impact.
- ⚠
Lack of detailed current financial statements (balance sheet, cash flow) in the real-time brief necessitates deeper due diligence beyond surface-level news.
Upcoming Risk Events
- 📅
Slower-than-expected OCS adoption rates impacting revenue growth targets
- 📅
Negative clinical trial results for CHOPS or future pipeline products
- 📅
Increased competitive pressure from new entrants or alternative technologies
When to Reconsider
- 🚪
Exit if quarterly revenue growth consistently falls below 15% year-over-year for two consecutive quarters.
- 🚪
Sell if operating margins show significant and sustained deterioration (e.g., falling below 5% for two consecutive quarters after achieving profitability).
- 🚪
Major regulatory setback for OCS or CHOPS that significantly delays or halts market access.
Unlock TMDX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Transmedics Group Inc (TMDX) Do?
Market Cap
$3.73B
Sector
Healthcare
Industry
Medical Devices
Employees
728
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Visit Transmedics Group Inc WebsiteInvestment Thesis
TransMedics is a leading innovator poised to transform the organ transplantation market with its proprietary OCS platform. Its expanding regulatory approvals, consistent revenue growth (albeit decelerating from peak), and ongoing pipeline advancements like CHOPS, solidify its competitive moat. The company's first year of profitability and strategic positioning for global market dominance present a compelling case for significant long-term growth and potential multi-bagger returns as its technology becomes the standard of care.
Is TMDX Stock Undervalued?
Unlock the full AI analysis for TMDX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
TMDX Price Targets & Strategy
12-Month Target
$157.07
Bull Case
$193.50
Bear Case
$96.70
Valuation Basis
Based on 6.5x forward P/S applied to estimated FY27 revenue of $890.4M, with 36.8M shares outstanding.
Entry Strategy
Consider dollar-cost averaging on dips, specifically around the $90-$95 range, which could represent a technical support level. Accumulate strategically ahead of Q1 2026 earnings.
Exit Strategy
Take partial profits if the stock approaches the $180-$200 range. Implement a stop-loss order if the stock breaks decisively below $90 on fundamental deterioration.
Portfolio Allocation
7-10% for aggressive investors, 3-5% for moderate risk tolerance, acknowledging its mid-cap growth profile in a niche, high-growth sector.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is TMDX Financially Healthy?
Valuation
P/E Ratio
19.63
EV/EBITDA
38.51
Price/Book
8.26
Price/Sales
7.97
Profitability
Gross Margin
59.92%
Operating Margin
17.93%
Net Margin
31.43%
Return on Equity
53.88%
Revenue Growth
37.13%
EPS
$4.68
Balance Sheet
Current Ratio
7.14
Quick Ratio
6.41
Debt/Equity
1.08
Cash Flow
EBITDA
$120.55M
Other
Beta (Volatility)
2.17
Does TMDX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is durable due to the specialized nature of organ transplantation, the significant investment required for R&D and clinical trials, and the stringent regulatory approval process. Each new label expansion and pipeline product like CHOPS reinforces this position.
Moat Erosion Risks
- •Technological obsolescence if a radically different, superior organ preservation method emerges.
- •Slower-than-expected regulatory approvals for new OCS indications or geographies.
- •Emergence of a well-funded competitor that can navigate regulatory hurdles and offer a 'good enough' solution at a lower cost.
TMDX Competitive Moat Analysis
Sign up to see competitive advantages
TMDX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish; retail investors are likely to be optimistic about continued innovation in critical medical procedures, but specific chatter is not detailed.
Institutional Sentiment
Neutral; previous analysis mentioned a notable analyst downgrade, but current brief offers no fresh analyst consensus or activity. The CHOPS announcement is positive but may not immediately sway ratings.
Insider Activity (Form 4)
Normal insider activity; no specific Form 4 filings detailing CEO/CFO buying or selling activity were flagged in the last 90 days.
Options Flow
Normal options activity; no specific data indicating unusual institutional positioning was identified in the research brief.
Earnings Intelligence
Next Earnings
2026-05-05
Surprise Probability
Medium
Historical Earnings Pattern
Based on prior analysis, the stock has shown sensitivity to guidance, with a notable analyst downgrade following the 2026 guidance. Investors will likely scrutinize both top-line growth and profitability trends.
Key Metrics to Watch
Competitive Position
Top Competitor
No direct, publicly traded 'best-in-class' competitor exists in portable organ perfusion; TransMedics is largely a market leader in this niche.
Market Share Trend
Gaining market share in the specific portable organ perfusion segment as OCS adoption increases and regulatory approvals expand its addressable market.
Valuation vs Peers
Likely trades at a premium to broader medical device companies due to its unique, proprietary technology, strong competitive moat, and market leadership in a critical niche.
Competitive Advantages
- •Proprietary OCS technology with extensive clinical validation and regulatory approvals (Intangible Assets/IP).
- •High switching costs for hospitals due to training, infrastructure, and established clinical protocols.
- •Significant regulatory barriers to entry for potential competitors in the organ preservation space.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive TMDX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Release on May 5, 2026 (after market close)
- •Updates on OCS adoption rates and procedural volume in Q1 earnings call
Medium-Term (6-18 months)
- •Progress and initial data from Controlled Hypothermic Organ Preservation System (CHOPS) heart/lung trials
- •Further regulatory label expansions for OCS into new organ types or expanded indications
- •Strategic partnerships with major hospital networks or OPOs to accelerate OCS adoption
Long-Term (18+ months)
- •Global market expansion for OCS technology beyond current geographies
- •Establishment of OCS as the standard of care for all major organ transplant procedures
- •Development of next-generation organ preservation technologies or integration with regenerative medicine
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for TMDX?
- ✓
Acceleration in OCS procedure volume and revenue growth exceeding current guidance.
- ✓
Positive clinical data readouts or accelerated regulatory timelines for CHOPS or other pipeline products.
- ✓
Consistent expansion of gross and operating margins, confirming profitability improvements.
Bull Case Analysis
See what could go right with Premium
Competing with TMDX
See how Transmedics Group Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Transmedics Group Inc TMDX | $3.7B | 9.0 | 19.6 | $566.4M | 31.4% | 37.1% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Transmedics Group Inc Makes Money
TransMedics Group Inc. operates by designing, developing, manufacturing, and selling a specialized medical device called the Organ Care System (OCS). The OCS is a portable technology that keeps donor organs, such as hearts, lungs, and livers, viable and functioning outside the human body for an extended period, significantly improving the logistics and outcomes of organ transplantation. The company generates revenue primarily from the sale of these OCS devices and the associated single-use disposable components required for each transplant procedure. Its customers are hospitals and organ procurement organizations globally that perform or facilitate organ transplantation. This business model is centered on pioneering proprietary technology in a critical, high-barrier-to-entry medical field, supported by extensive clinical validation and regulatory approvals.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Transmedics Group Inc (TMDX)?
As of April 28, 2026, Transmedics Group Inc has a DVR Score of 9.0 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Transmedics Group Inc?
Transmedics Group Inc's market capitalization is approximately $3.7B. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Transmedics Group Inc use?
TMDX is the ticker symbol for Transmedics Group Inc. The company trades on the NGM.
What is the risk level for TMDX stock?
Our analysis rates Transmedics Group Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of TMDX?
Transmedics Group Inc currently has a price-to-earnings (P/E) ratio of 19.6. This is in line with broader market averages.
Is Transmedics Group Inc's revenue growing?
Transmedics Group Inc has reported revenue growth of 37.1%. The company is showing strong top-line momentum.
Is TMDX stock profitable?
Transmedics Group Inc has a profit margin of 31.4%. This indicates strong profitability.
How often is the TMDX DVR analysis updated?
Our AI-powered analysis of Transmedics Group Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 28, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TMDX (Transmedics Group Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.